Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies

Supplements and Featured PublicationsBTK Inhibitors in B-Cell Lymphomas
Volume 1
Issue 1

In Partnership With:

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the utility of BTK inhibitors in B-cell malignancies.

BTK inhibitors target an enzyme that is necessary for B​-cell growth, says Leslie. ​Moreover, there are several approved indications ​for BTK inhibitors in chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, mantle cell lymphoma ​(MCL), and ​Waldenström macroglobulinemia.

Notably, ibrutinib (Imbruvica) ​and acalabrutinib (Calquence) ​are 2 BTK inhibitors that are approved for patients with B-cell malignancies. Moreover, zanubrutinib (Brukinsa) is currently approved in relapsed/refractory MCL and is the subject of ongoing investigation in other B-cell malignancies, Leslie concludes. 

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine